

## References

1. Stadnytskyi V, Bax CE, Bax A, Anfinrud P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. *Proceedings of the National Academy of Sciences*. 2020;117(22):11875-7. Available at: <https://www.pnas.org/doi/abs/10.1073/pnas.2006874117>
3. Quesada JA, Lopez-Pineda A, Gil-Guillen VF, Arriero-Marin JM, Gutierrez F, Carratala-Munuera C. Incubation period of COVID-19: A systematic review and meta-analysis. *Rev Clin Esp (Barc)*. 2021 Feb;221(2):109-17. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33998486>
4. Alene M, Yismaw L, Assemie MA, Ketema DB, Gietaneh W, Birhan TY. Serial interval and incubation period of COVID-19: a systematic review and meta-analysis. *BMC Infect Dis*. 2021 Mar 11;21(1):257. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33706702>
5. Rai B, Shukla A, Dwivedi LK. Incubation period for COVID-19: a systematic review and meta-analysis. *Z Gesundh Wiss*. 2021 Feb 23:1-8. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33643779>
6. Elias C, Sekri A, Leblanc P, Cucherat M, Vanhems P. The incubation period of COVID-19: A meta-analysis. *Int J Infect Dis*. 2021 Mar;104:708-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33548553>
7. Xin H, Wong JY, Murphy C, Yeung A, Taslim Ali S, Wu P, et al. The Incubation Period Distribution of Coronavirus Disease 2019: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2021 Dec 16;73(12):2344-52. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34117868>
8. Homma Y, Katsuta T, Oka H, Inoue K, Toyoshima C, Iwaki H, et al. The incubation period of the SARS-CoV-2 B.1.1.7 variant is shorter than that of other strains. *J Infect*. 2021 Aug;83(2):e15-e7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34146596>
9. Snell LB, Awan AR, Charalampous T, Alcolea-Medina A, Douthwaite ST, Edgeworth JD, et al. SARS-CoV-2 variants with shortened incubation periods necessitate new definitions for nosocomial acquisition. *J Infect*. 2021 Aug 30 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34474059>
10. Li B, Deng A, Li K, Hu Y, Li Z, Shi Y, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. *Nat Commun*. 2022 Jan 24;13(1):460. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35075154>
11. Tiecco G, Storti S, Degli Antoni M, Focà E, Castelli F, Quiros-Roldan E. Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. *International Journal of Molecular Sciences*. 2022;23(4):1987. Available at: <https://www.mdpi.com/1422-0067/23/4/1987>
12. Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. *Science*. 2021;373(6551):eabi5273. Available at: <https://www.science.org/doi/abs/10.1126/science.abi5273>
13. Li L, Han ZG, Qin PZ, Liu WH, Yang Z, Chen ZQ, et al. Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study. *PLoS Negl Trop Dis*. 2022 Jan;16(1):e0010048. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34986169>
14. Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. *EClinicalMedicine*. 2021 Oct;40:101129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34541481>
15. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Euro Surveill*. 2021 Dec;26(50) Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34915975>

16. Jansen L, Tegomoh B, Lange K, Showalter K, Figliomeni J, Abdalhamid B, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster - Nebraska, November-December 2021. *MMWR Morb Mortal Wkly Rep.* 2021 Dec 31;70(5152):1782-4. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34968376>
17. Backer JA, Eggink D, Andeweg SP, Veldhuijzen IK, van Maarseveen N, Vermaas K, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared to Delta variant in the Netherlands, 13 – 26 December 2021. *medRxiv.* 2022:2022.01.18.22269217. Available at: <https://www.medrxiv.org/content/medrxiv/early/2022/01/28/2022.01.18.22269217.full.pdf>
18. Ge Y, Martinez L, Sun S, Chen Z, Zhang F, Li F, et al. COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province, China. *JAMA Internal Medicine.* 2021;181(10):1343-50. Available at: <https://doi.org/10.1001/jamainternmed.2021.4686>
19. United Kingdom Health Security Agency. COVID-19: epidemiology, virology and clinical features. 2022 Available at: <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-background-information/wuhan-novel-coronavirus-epidemiology-virology-and-clinical-features>
20. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun.* 2021 Jan 11;12(1):267. Available at: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801729/pdf/41467\\_2020\\_Article\\_20568.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801729/pdf/41467_2020_Article_20568.pdf)
21. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. *N Engl J Med.* 2021 Dec 23;385(26):2489-91. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34941024>
22. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *Lancet Infect Dis.* 2022 Feb;22(2):183-95. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34756186>
23. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Factors affecting COVID-19 period of communicability – what we know so far. Toronto, Canada: Queen’s Printer for Ontario; 2021. Available at: <https://www.publichealthontario.ca/en/diseases-and-conditions/infectious-diseases/respiratory-diseases/novel-coronavirus/what-we-know>
24. Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.* 2021 Feb;27(2):387-9.
25. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe.* 2021 Jan;2(1):e13-e22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33521734>
26. Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. *Infect Control Hosp Epidemiol.* 2020:1-10. Available at: <https://pubmed.ncbi.nlm.nih.gov/33077007>
27. Heylen L, Oris E, Wollants E, Maes P, Van Kerrebroeck M, Peeters J, et al. 128 days of SARS-CoV-2 viral shedding in a haemodialysis patient. *Clinical Kidney Journal.* 2021;14(4):1284-6. Available at: <https://doi.org/10.1093/ckj/sfab004>
28. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell.* 2020 Dec 23;183(7):1901-12.e9.

29. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. *New England Journal of Medicine*. 2020;383(23):2291-3. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMc2031364>
30. Molina LP, Chow SK, Nickel A, Love JE. Prolonged Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an Obstetric Patient With Antibody Seroconversion. *Obstetrics and gynecology*. 2020 Oct;136(4):838-41.
31. Korea Central Disaster Control and Prevention. Findings from Investigation and analysis of re-positive cases. Seoul: KCDC; 2020. Available at: [https://www.mofa.go.kr/eng/brd/m\\_22743/view.do?seq=3&srchFr=&srchTo=&srchWord=&srchTp=&multi\\_itm\\_seq=0&itm\\_seq\\_1=0&itm\\_seq\\_2=0&company\\_cd=&company\\_nm=&page=1&titleNm=](https://www.mofa.go.kr/eng/brd/m_22743/view.do?seq=3&srchFr=&srchTo=&srchWord=&srchTp=&multi_itm_seq=0&itm_seq_1=0&itm_seq_2=0&company_cd=&company_nm=&page=1&titleNm=)
32. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020 May;26(5):672-5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32296168>
33. Jones TC, Biele G, Muhlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. *Science*. 2021 Jul 9;373(6551) Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34035154>
34. Neant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, et al. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. *Proc Natl Acad Sci U S A*. 2021 Feb 23;118(8) Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33536313>
35. National Institute of Infectious Diseases Japan. Active epidemiological investigation on SARS-CoV-2 infection caused by Omicron variant (Pango lineage B.1.1.529) in Japan: preliminary report on infectious period. 2022 Available at: <https://www.niid.go.jp/niid/en/2019-ncov-e/10884-covid19-66-en.html>
36. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ*. 2020 Apr 21;369:m1443. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32317267>
37. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*. 2020 2020/05/01/;20(5):565-74. Available at: <https://www.sciencedirect.com/science/article/pii/S1473309920301961>
38. Benefield AE, Skrip LA, Clement A, Althouse RA, Chang S, Althouse BM. SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of coronavirus viral load from 66 studies. *medRxiv2020*. p. 2020.09.28.20202028.
39. Yonker LM, Neilan AM, Bartsch Y, Patel AB, Regan J, Arya P, et al. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. *The Journal of pediatrics*. 2020 Dec;227:45-52.e5.
40. Rasmussen AL, Popescu SV. SARS-CoV-2 transmission without symptoms. *Science*. 2021;371(6535):1206-7. Available at: <https://www.science.org/doi/abs/10.1126/science.abf9569>
41. Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. *Emerging infectious diseases*. 2020 Jul;26(7)
42. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2021 Dec 1;4(12):e2137257. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34905008>

43. Ra SH, Lim JS, Kim GU, Kim MJ, Jung J, Kim SH. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. *Thorax*. 2021 Jan;76(1):61-3. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32963115>
44. Glenet M, Lebreil AL, Heng L, N'Guyen Y, Meyer I, Androletti L. Asymptomatic COVID-19 Adult Outpatients identified as Significant Viable SARS-CoV-2 Shedders. *Sci Rep*. 2021 Oct 18;11(1):20615. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34663858>
45. Zuin M, Gentili V, Cervellati C, Rizzo R, Zuliani G. Viral Load Difference between Symptomatic and Asymptomatic COVID-19 Patients: Systematic Review and Meta-Analysis. *Infect Dis Rep*. 2021 Jul 16;13(3):645-53. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34287354>
46. Qiu X, Nergiz AI, Maraolo AE, Bogoch, II, Low N, Cevik M. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review. *Clin Microbiol Infect*. 2021 Apr;27(4):511-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33484843>
47. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020 May 28;382(22):2081-90. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32329971>
48. Ge Y, Martinez L, Sun S, Chen Z, Zhang F, Li F, et al. COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province, China. *JAMA Intern Med*. 2021 Oct 1;181(10):1343-50. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34424260>
49. Chun JY, Baek G, Kim Y. Transmission onset distribution of COVID-19. *Int J Infect Dis*. 2020 Oct;99:403-7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32771633>
50. Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. *Nature Medicine*. 2022 2022/04/08 Available at: <https://doi.org/10.1038/s41591-022-01816-0>
51. Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med*. 2021 Aug 9 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34369565>
52. Public Health England. Increased household transmission of COVID-19 cases associated with SARS-CoV-2 Variant of Concern B.1.617.2: a national case control study. London: PHE; 2021. Available at: <https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa>
53. Public Health England. Risk assessment for SARS-CoV-2 variant: Delta. London: PHE; 2021. Available at: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1005395/23\\_July\\_2021\\_Risk\\_assessment\\_for\\_SARS-CoV-2\\_variant\\_Delta.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005395/23_July_2021_Risk_assessment_for_SARS-CoV-2_variant_Delta.pdf)
54. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Euro Surveill*. 2021 Jun;26(24) Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34142653>
55. Ito K, Piantham C, Nishiura H. Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark. *Journal of medical virology*. 2022 May;94(5):2265-8.
56. Petros BA, Turcinovic J, Welch NL, White LF, Kolaczyk ED, Bauer MR, et al. Early Introduction and Rise of the Omicron Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant in Highly Vaccinated University Populations. *Clinical Infectious Diseases*. 2022 Available at: <https://doi.org/10.1093/cid/ciac413>
57. Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant. *medRxiv*. 2022:2022.01.13.22269257.

Available at:

<https://www.medrxiv.org/content/medrxiv/early/2022/01/14/2022.01.13.22269257.full.pdf>

58. Sentis C, Billaud G, Bal A, Frobert E, Bouscambert M, Destras G, et al. SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant. *Viruses*. 2022 Apr 28;14(5)
59. Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. *Journal of medical virology*.n/a(n/a) Available at: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.27927>
60. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. *Nature*. 2022 Mar;603(7902):700-5.
61. European Centre for Disease Prevention and Control. Guidance on ending the isolation period for people with COVID-19, third update, 28 January 2022. Stockholm: ECDC; 2022. Available at: <https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-for-discharge-and-ending-of-isolation-of-people-with-COVID-19-third-update.pdf>
62. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. SARS-CoV-2 Omicron VOC Transmission in Danish Households. *medRxiv*. 2021:2021.12.27.21268278. Available at: <https://www.medrxiv.org/content/medrxiv/early/2021/12/27/2021.12.27.21268278.full.pdf>